130 related articles for article (PubMed ID: 31112620)
1. Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation.
Sukumar S; Gulilat M; Linton B; Gryn SE; Dresser GK; Alfonsi JE; Schwarz UI; Kim RB; Schwartz JB
J Am Geriatr Soc; 2019 Sep; 67(9):1902-1906. PubMed ID: 31112620
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
Zeitouni M; Giczewska A; Lopes RD; Wojdyla DM; Christersson C; Siegbahn A; De Caterina R; Steg PG; Granger CB; Wallentin L; Alexander JH;
J Am Coll Cardiol; 2020 Mar; 75(10):1145-1155. PubMed ID: 32164888
[TBL] [Abstract][Full Text] [Related]
3. Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes.
Campbell AM; Pae E; Lee E; Jacisin T; Price A; DeAngelo J
Ann Pharmacother; 2024 Jun; 58(6):572-580. PubMed ID: 37712551
[TBL] [Abstract][Full Text] [Related]
4. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study.
Inoue H; Umeyama M; Yamada T; Hashimoto H; Komoto A; Yasaka M
J Cardiol; 2020 Feb; 75(2):208-215. PubMed ID: 31421933
[TBL] [Abstract][Full Text] [Related]
6. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.
Suwa M; Morii I; Kino M
Circ J; 2019 Apr; 83(5):991-999. PubMed ID: 30918237
[TBL] [Abstract][Full Text] [Related]
8. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.
McHorney CA; Peterson ED; Laliberté F; Germain G; Nelson WW; Crivera C; Schein J; Lefebvre P
Clin Ther; 2016 Nov; 38(11):2477-2488. PubMed ID: 27789043
[TBL] [Abstract][Full Text] [Related]
10. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
[TBL] [Abstract][Full Text] [Related]
11. A study on indices of apixaban anticoagulation: A single-center prospective study.
Komiyama M; Miyazaki Y; Wada H; Iguchi M; Abe M; Ogawa H; Akao M; Yamakage H; Satoh-Asahara N; Sunagawa Y; Morimoto T; Hasegawa K
J Pharmacol Sci; 2018 Jun; 137(2):105-109. PubMed ID: 29866521
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
Coleman CI; Peacock WF; Antz M
Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Apixaban Prescribing Patterns for Nonvalvular Atrial Fibrillation in Hospitalized Patients.
Gibson CM; Smith CB; Davis S; Scalese MJ
Ann Pharmacother; 2018 Jan; 52(1):54-59. PubMed ID: 28799408
[TBL] [Abstract][Full Text] [Related]
14. Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation.
Thomas A; Fang MC; Kogan S; Hubbard CC; Friedman PN; Gong L; Klein TE; Nutescu EA; O'Brien TJ; Tuck M; Perera MA; Schwartz JB
JACC Adv; 2022 Jun; 1(2):. PubMed ID: 37961076
[TBL] [Abstract][Full Text] [Related]
15. Initial apixaban dosing in patients with atrial fibrillation.
Buchholz A; Ueberham L; Gorczynska K; Dinov B; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
Clin Cardiol; 2018 May; 41(5):671-676. PubMed ID: 29542830
[TBL] [Abstract][Full Text] [Related]
16. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L;
JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Terayama Y
Curr Med Res Opin; 2018 Sep; 34(9):1627-1634. PubMed ID: 29772946
[TBL] [Abstract][Full Text] [Related]
19. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis.
Kufel WD; Zayac AS; Lehmann DF; Miller CD
Pharmacotherapy; 2016 Nov; 36(11):e166-e171. PubMed ID: 27643979
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.
Yamazaki-Nishioka M; Kogiku M; Noda M; Endo S; Takekawa M; Kishi H; Ota M; Notsu Y; Shimizu M; Yamazaki H
Xenobiotica; 2019 Sep; 49(9):1001-1006. PubMed ID: 30216091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
